Grifols announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation, the first for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses. The Procleix ArboPlex Assay will be available in all markets accepting the CE mark certification after completion of any additional registration and notification requirements.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
- Grifols says CNMV validates financial statements, indebtedness of Grifols
- Grifols sees addressing 2025 maturities ‘efficiently’ in first half of 2024
- Largest borrow rate increases among liquid names
- Grifols downgraded to Sell at Deutsche Bank on ‘problem’ of cash flow guidance
